Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
aTyr Pharma Inc
471ACurrent price
3.3 EUR
0 EUR (0.00%)
Last closed
3.32 EUR
Company
www.atyrpharma.com
ISIN
US0021202025
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
221 702 543 EUR
Yield for 12 month
+235.03 %
1Y
3Y
5Y
10Y
15Y
471A
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. Address: 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18.35 EURP/E ratio
–Dividend Yield
–Current Year
+335 174 EUR
Last Year
+9 861 517 EUR
Current Quarter
–
Last Quarter
+223 133 EUR
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures 471A
1 year
3 years
5 years
10 years
EBITDA
-62 559 300 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-32.74 %
PEG Ratio
–
Return On Equity TTM
-61.76 %
Wall Street Target Price
18.35 EUR
Revenue TTM
595 041 EUR
Book Value
1.45 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100 %
Dividend Yield
–
Gross Profit TTM
-32 810 263 EUR
Earnings per share
-0.84 EUR
Diluted Eps TTM
-0.84 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 471A
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 471A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:14
Payout Ratio
–
Last Split Date
01.07.2019
Dividend Date
–
Stock Valuation 471A
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
292.2672
Price Sales TTM
372.5833
Enterprise Value EBITDA
-0.628
Price Book MRQ
2.8473
Financials 471A
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 471A
For 52 weeks
1 EUR
3.3 EUR
50 Day MA
2.15 EUR
Shares Short Prior Month
–
200 Day MA
1.77 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart